← Leaderboards
Dora Ilyasova
Duke University
$822,294
Attributed
$822,294
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $359.5K · FY2009–11$500K$375K$250K$125K$0
'09
'10
'11
Funding mix
By agency
NIH$822,294 · 2
By mechanism
R01$822,294 · 2
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- Judith A Voynow$8,542,123
- Michael Barry Kastan$65,974,699
- David Matus$3,062,861
- Duane A. Mitchell$34,257,734
- Richard G Fehon$12,746,988
Others in their field
Top investigators on “Epidemiology”
- David Heimbrook · Leidos Biomedical Research, Inc.$390,770,069
- George R Seage · Abt Associates, Inc.$299,251,523
- Jeffrey P Krischer · University Of South Florida$264,076,260
- Barbara Driver · Westat, Inc.$221,167,491
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$206,739,528
- James Dennis Neaton · Northwestern University$203,539,316
Research focus
EpidemiologyRisk FactorsReportingDiagnosisAntioxidantsEpidemicEarly TreatmentDiabetic PatientExpectationDiabetes RiskCharacteristicsDisorder PreventionBiomarkerArchivesAtherosclerosisCohort StudiesClinical TrialsCohortDeteriorationDesignBaseDiabetes MellitusBody Mass IndexCross-Sectional Studies
Grant awards (4)
Urinary F2-Isoprostanes As A New Biomarker For The Risk Of Type 2 Diabetes$263,858
R01 · FY2011 · DK · contact PI
Urinary F2-isoprostanes as a new biomarker for the risk of type 2 diabetes$259,628
R01 · FY2010 · DK · contact PI
Meningioma: Risk Factors and Quality of Life$99,873
R01 · FY2010 · CA · contact PI
Urinary F2-isoprostanes as a new biomarker for the risk of type 2 diabetes$198,935
R01 · FY2009 · DK · contact PI